HCmed Innovations has introduced its new Pulmogine mesh nebulizer, which is capable of delivering a variety of drugs for inhalation, including biologics and high viscosity solutions. The nebulizer is customizable for specific formulations, and the company says that it can effectively deliver drugs such as dornase alfa, colistin, and tobramycin for the treatment of cystic fibrosis.
Earlier this year, HCmed announced plans for a new R&D center and production facility in the Wuxi International Life Science Innovation Park in Wuxi, China. The company’s Deepro mesh nebulizer is approved in multiple countries, including Taiwan, Indonesia, and Brazil.
HCmed said that it will display the Pulmogine nebulizer at several upcoming meetings, including DDL 2019.
Read the HCmed press release.
